Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pediatric clinical pharmacology and its implications for antiretroviral drug development

Pediatric clinical pharmacology and its implications for antiretroviral drug development Pediatric clinical pharmacology and its implications for antiretroviral drug development Jennifer King and Edward Acosta University of Alabama at Birmingham School of Purpose of review Medicine, Division of Clinical Pharmacology, Highly active antiretroviral therapy, which is widely available throughout developed Birmingham, Alabama, USA countries, has become increasingly effective for treating the human immunodeficiency Correspondence to Jennifer R. King, PharmD, virus. In contrast, access to antiretroviral therapy in low-income countries is difficult at University of Alabama at Birmingham School of Medicine, Division of Clinical Pharmacology, best. Thus, antiretroviral therapy for pediatric patients in resource-rich countries 1530 3rd Avenue South, VH101A, Birmingham, predominantly targets new drugs, and in low-income countries focuses on acquiring AL 35294-0019, USA Tel: +1 205 934 2696; fax: +1 205 934 6201; inexpensive, generic antiretroviral compounds available in pediatric-friendly e-mail: Jennifer.king@ccc.uab.edu formulations. Regardless of the economic region, success of antiretroviral therapy in pediatric patients depends upon our understanding of the physiological differences in Current Opinion in HIV and AIDS 2008, 3:272– drug absorption and disposition that occur with age, and our ability to adjust antiretroviral dosing according to these changes. The purpose of this review is to describe these differences and present recently published pharmacokinetic data of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Pediatric clinical pharmacology and its implications for antiretroviral drug development

Acosta, Edward
Current Opinion in HIV and Aids , Volume 3 (3) – May 1, 2008
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/pediatric-clinical-pharmacology-and-its-implications-for-nLidbo3536

References (27)

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e3282f64530
pmid
19372978
Publisher site
See Article on Publisher Site

Abstract

Pediatric clinical pharmacology and its implications for antiretroviral drug development Jennifer King and Edward Acosta University of Alabama at Birmingham School of Purpose of review Medicine, Division of Clinical Pharmacology, Highly active antiretroviral therapy, which is widely available throughout developed Birmingham, Alabama, USA countries, has become increasingly effective for treating the human immunodeficiency Correspondence to Jennifer R. King, PharmD, virus. In contrast, access to antiretroviral therapy in low-income countries is difficult at University of Alabama at Birmingham School of Medicine, Division of Clinical Pharmacology, best. Thus, antiretroviral therapy for pediatric patients in resource-rich countries 1530 3rd Avenue South, VH101A, Birmingham, predominantly targets new drugs, and in low-income countries focuses on acquiring AL 35294-0019, USA Tel: +1 205 934 2696; fax: +1 205 934 6201; inexpensive, generic antiretroviral compounds available in pediatric-friendly e-mail: Jennifer.king@ccc.uab.edu formulations. Regardless of the economic region, success of antiretroviral therapy in pediatric patients depends upon our understanding of the physiological differences in Current Opinion in HIV and AIDS 2008, 3:272– drug absorption and disposition that occur with age, and our ability to adjust antiretroviral dosing according to these changes. The purpose of this review is to describe these differences and present recently published pharmacokinetic data of

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: May 1, 2008

There are no references for this article.